BTIG Remains a Buy on Ardelyx (ARDX) With a $14 PT

Ardelyx Inc. (NASDAQ:ARDX) is one of the best biotech penny stocks to buy right now. On July 29, BTIG analyst Julian Harrison maintained a Buy rating on Ardelyx Inc. (NASDAQ:ARDX), retaining the price target of $14.00 and supporting the rating with the company’s market positioning and growth potential.

An aerial view of a pharmaceutical facility, showing the size and scale of the company’s operations.

The analyst told investors that a significant factor supporting the optimistic rating is the expected growth in Ibsrela’s revenue, with projections of a 21% growth compared to last quarter, and a strong estimated growth for the rest of the year.

Harrison added that this growth trajectory is supported by the attainable $1 billion peak net sales target, which appears conservative, provided Ibsrela’s unique market position as the only non-secretagogue treatment option and the current market conditions.

The analyst added that Ibsrela’s market opportunity is further supported by the fact that up to 50% of IBS-C patients do not exhibit adequate response to the existing treatments, which leaves a gap that Ibsrela can fill.

Ardelyx Inc. (NASDAQ:ARDX) develops and commercializes biopharmaceutical products. It is also involved in the development of an innovative platform that discovers new biological mechanisms and pathways to develop efficacious therapies, reducing the drug-drug interactions and side effects of traditional medicines.

While we acknowledge the potential of ARDX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARDX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.